Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

Review (65 studies; n= 14,200) found both ultra-long-acting and long-acting insulin were superior to intermediate-acting insulin in reducing HbA1c, fasting plasma glucose, weight gain, and incidence of major, serious, or nocturnal hypoglycaemia.

Source:

British Journal of General Practice